`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`REMARKS
`
`Claims 15, 17-19, 24, 25, 27-32, 35-44 were allowed in pending in the subject
`
`application. In this Amendment, Applicants have amendedclaims 15, 28, 36 and 38-40.
`
`Claims 15 and 38-40 have been amendedto include the terms “(a)” and “(b)”
`
`before the first recitation of the terms “1-[(4-methyl-quinazolin-2-yl)methy1]-3-methyl-7-
`
`(2-butyn- 1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-xanthine” and “metformin,” respectively.
`
`As amended, these claims now recite a method of treatment comprising both (a) 1-[(4-
`
`methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-
`
`xanthine and (b) metformin. Applicants believe these amendments to claims 15 and 38-40
`
`more precisely recite the subject matter of these claims.
`
`Claim 28 has been amendedto replace the term “500-2850 mg” with the term “500
`
`mg to 2850 mg.”
`
`Claim 36 has been amendedto replace the term “an” which precedes the term
`
`“pharmaceutically” in the last line of the claim with the term “a.”
`
`Claims 38-40 have been further amended to include the term “in” before the phrase
`
`“the form of a fixed combination.”
`
`Support for the above amendments can be found throughoutthe original
`
`specification and in the original claims.
`
`Each of the above amendments merely embodies the correction of formal matters
`
`without changing the scope of the allowed claims. Pursuant to MPEP § 714.16(a),
`
`Applicants believe the amendments are (A) needed for proper disclosure or protection of
`
`the invention, and (B) require no substantial amount of additional work onthe part of the
`
`office.
`
`entry.
`
`No new matter is added by this amendment, and Applicants respectfully requestits
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`CONCLUSION
`
`Applicants respectfully request prompt consideration of the amended claims and
`
`entry of this amendment. No additional fee is believed due. However, if any additional
`
`fee is due, the Examineris authorized to charge the fee to Applicants’ Deposit Account
`
`No, 02-2955.
`
`If a telephonic or personal interview is deemed necessary in connection with this
`
`application, the Examiner is kindly requested to contact the undersigned at the telephone
`
`numberlisted below.
`
`Respectfully submitted,
`
`/David L. Kershner/
`David L. Kershner
`Attorney for Applicant(s)
`Reg. No. 53,112
`
`Patent Department
`Boehringer Ingelheim Corp.
`900 Ridgebury Road
`P.O. Box 368
`Ridgefield, CT 06877
`Tel.:
`(203) 448-1844
`Fax: (203) 837-5616
`
`Date: July 29, 2015
`
`